statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	455
SG - Singapore	228
RU - Federazione Russa	173
IT - Italia	117
VN - Vietnam	100
CN - Cina	84
BR - Brasile	50
NL - Olanda	45
DE - Germania	32
HK - Hong Kong	25
FI - Finlandia	24
FR - Francia	15
CA - Canada	13
CI - Costa d'Avorio	12
IE - Irlanda	12
UA - Ucraina	11
GB - Regno Unito	7
IN - India	5
JP - Giappone	5
MX - Messico	5
BD - Bangladesh	4
ES - Italia	4
IQ - Iraq	4
TH - Thailandia	4
AR - Argentina	3
AT - Austria	3
ID - Indonesia	3
KR - Corea	3
PK - Pakistan	3
SE - Svezia	3
CO - Colombia	2
EC - Ecuador	2
KZ - Kazakistan	2
MA - Marocco	2
VE - Venezuela	2
BE - Belgio	1
BG - Bulgaria	1
BY - Bielorussia	1
CL - Cile	1
ET - Etiopia	1
GP - Guadalupe	1
GR - Grecia	1
HT - Haiti	1
JM - Giamaica	1
LB - Libano	1
LT - Lituania	1
MD - Moldavia	1
MK - Macedonia	1
MY - Malesia	1
NA - Namibia	1
NO - Norvegia	1
PH - Filippine	1
PL - Polonia	1
PY - Paraguay	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TN - Tunisia	1
TR - Turchia	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	1.488

Nome	#
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR	162
A complicated association between two different genetic rare disorders: Cystic Fibrosis and Spinal Muscular Atrophy	157
Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis.	141
Positive expiratory pressure treatment: efficacy in pulmonary diseases	130
Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis	129
Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.	128
Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease	121
Aspergillosi broncopolmonare	106
Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis.	106
Positive expiratory pressure treatment: efficacy in pulmonary diseases.	101
Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis.	97
Home physiotherapists assisting follow-up treatment in cystic fibrosis: a multicenter observational study	95
Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in a Cystic Fibrosis Child With L1077P Mutation	31
Totale	1.504

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	9	0	0	0	0	0	0	0	0	0	1	4	4
2021/2022	74	0	0	3	0	0	5	4	3	11	2	23	23
2022/2023	131	11	9	2	9	19	9	2	9	27	26	8	0
2023/2024	120	3	14	17	11	8	13	7	18	1	5	15	8
2024/2025	411	16	25	3	11	17	33	26	36	33	25	153	33
2025/2026	652	69	38	84	59	138	23	60	48	88	45	0	0
Totale													1.504